Volume : 12, Issue : 10, October – 2025
Title:
NASAL SPRAY FOR DECONGESTANT THERAPY
Authors :
Akash A. Vikhar*, Shubham U Tikait, Dr. Swati P Deshmukh
Abstract :
Nasal spray formulations have emerged as a reliable, non-invasive, and rapid-acting alternative for decongestant therapy. The common cold has no known cure, and the only way to treat nasal congestion is with symptomatic medications. The nasal route offers both local and systemic drug delivery advantages, including avoidance of first-pass metabolism, rapid onset of action, and high patient compliance. Nasal sprays are preferred over drops or powders due to better dose precision and patient acceptability. However, limitations include limited absorption for large or polar drugs, mucosal irritation risks, enzymatic degradation, and volume constraints. Continuous improvements in formulation technology, such as preservative-free systems and mucoadhesive agents, promise enhanced safety and therapeutic performance in future nasal drug products.
Keywords: Nasal cavity, Anatomy, Absorption,mechanism,challenges,Adv,Dis, Application .
Cite This Article:
Please cite this article in press Akash A. Vikhar et al., Nasal Spray For Decongestant Therapy, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1) Sharma PK Choudhari P , Kolsure P, Ajab A , Varia N. Recent trends in nasal drug delivery system – an overview. 2006; 5(4), 56-69
2) Naclerio RM , Bachert C, Baraniuk JN. Pathophysiology of nasal congestion. Int Med 2010;3:47-57
3) Taverner D, and Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev ;1 CD001953, 2007.
4) Debjit Bhowmik, Rakesh Kharel, Jyoti Jaiswal, Chiranjib, Biswajit and K.P. Sampath Kumar for Innovative approaches for nasal drug
5) 5.S. Caleb Freeman, David A. Karp; I.Kahwaji for Physiology of, Nasal
6) Akshay S. Sidam, Piyush G. Paifhan , Komal V. Shinde , Dr. Nilesh O Chachda, Khushi M. Kongre for ” A Comprehensive Review on Oxymetazoline Hydrochloride as Nasal Spray.
7) A Akerlund , K E Arfos , M Bende, M Intaglietta for Effect of oxymetazoline on nasal and sinus mucosal blood flow ijnthe rabbit as measured with laser dropper flowmetry.
8) Emmeline Marttin , Nicolas G.M Schipper, J.Coos Verhoef, Frans W.H.M Merkus for Nasal mucociliary clearance as a factor in nasal drug delivery
9) Christine Graf, Andreas Bernkop- Schnutch, Alena Egyed, Christine Koller, Eva Prieschl – Grassauer , Martina Morokutti- Kurz for development of nasl spray containing Xylometazoline hydrochloride and iota-carrageenam for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis.
10) Bradley Marple, Peter Roland , Michael Benninger for Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions.
11) Vitthal Kulkarni and Charles Shaw DPT Laboratories Ltd for An examination of nasal spray formulation parameters and excipients and their influence on key in vitro tests.
12) Chrystalla Protopapa , Angeliki Siamidi , Panagoula Pavlaou, Marilena Vlachou for Excipients Used for Modified Nasal drug Delivery: A mini -Review of the Recent Advances
13) Zainab Jassim E , Entidhar Al-Amkam J. Drugs Invention Today , 2018 ; 12(1):2860-2861
14) Thorat S. Scholars Journal of applied medical science s(SJAMS) , 2016 ; 4(8D): 2980-2981.
15) Md. Meddi H, Md. Mizanur R, lutfulkabir AK, Ghosh AK , Mahbub H, Md. Salimul K, Harun R. International journal of Pharmacy and therapeutics ,2016;7(4):190-192
16) Patil VB, Kalkotwar RS, Patel A, Tathe S , Jadhav VB . Journal of drug delivery and therapeutics, 2012; 2(4):1-3
17) Md. Mehdi H, Md. Mizanur R , lutfulkabir AK Ghosh AK, Mahbub H, Md. Salimul K, Harun R. International journal of pharmacy and therapeutics, 2016; 7(4):195-196.
18) Karpagavalli L, Gopalasatheeskumar K, Narayanan N, Isakki RA , Hari PJ, Janarthanan S. World journal of pharmaceutical research, 2017; 6(2):402-403.
19) Alagusundaram M, Chengaiah B, Gnanaprakash K, Ramkanth S, Madhusudhana C, Dhachinamoorthi D. International journal of research in pharmaceutical sciences, 2010 ; 1(4) : 461-462
20) Ramesh RP, Mahesh C, Patil O, e-journal of science and technology, 2009; 3:1-21
21) Davis SS, Illum L. clinical Pharmacokinetics 2003; 42(13):1107-1128
22) Arora P, Sharma S, Garg S. Drug Discovery Today, 2003;7(18):967-975.
23) Chaturvedi M, Kumar M Pathak K. Journal of Advanced Pharmaceutical Technology and Research, 2011; 4:215-222
24) Dhakar RC, Maurya SD, Tilak VK, Gupta AK. International journal on Drug Delivery, 2011; 3:194-208
25) Brain JD, Valberg PA, Am Rev Respir Dis., 1979;1(20):1325-1373.
26) Behl CR, Pimplaskar HK , Sileno AP , Xia WJ , Gries WJ, deMeireles JC , et al. Adv Drug Delivery Rev. 1998;29:117-133
27) Foo MY , Cheng YS , Su WC , Donovan MD. J Aerosol MD., 2007;20:495-508.
28) Md. Mehdi H, Md Mizanur R, lutfulkabir AK, Ghosh AK, Mahbub H, Md Salimul ka, Harun R. International journal of pharmacy and therapeutics,2016;7(4):190-192
29) Boukarin C, AbouJs, Bahnam R, Barada R, KyriacosS. Drug Test Anal., 2009; 1 :146-148
30) Brain JD , Valberg PA. Am Rev Respir Dis ., 1979;120:1325-1373
31) Patel , D.,and Patel M, (2014). Formulation and evaluation of Nasal Spray of Antihistaminic Drug. Int.J. Pharm.Sci.Rev.,27(1),74-80.